Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDP-101 in Plasma Cell Disorders Including Multiple Myeloma
NCT04879043Phase 2Recruiting
- Sponsor
- Heidelberg Pharma AG
- Start
- Feb 2022
- Primary completion
- Mar 2028
- Modality
- Cyclic Peptides, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of HDP-101 in multiple myeloma (MM) and plasma cell disorder (PCD), sponsored by Heidelberg Pharma AG. Primary endpoints: Dose-Limiting Toxicity at 21 days and Objective Response Rate at 1 year. Started Feb 2022; status: recruiting.
02
Drugs
HDP-101
03
Conditions
multiple myeloma (MM)plasma cell disorder (PCD)
Beyond the preview
Go deeper on NCT04879043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879043.